#experimental therapies

Early treatment is linked to a smaller viral reservoir, but blocking IL-10 and PD-1 might control the virus in those with chronic infection.

The novel HIV capsid inhibitor also shows promise for previously untreated people.

The government-wide effort aims to develop the next generation of COVID-19 treatments to prepare the U.S. to respond to future virus threats

An islatravir PrEP implant could prevent HIV for a year.

A Brazilian man with HIV is no longer in remission after more than 15 months off treatment.

Molnupiravir, previously studied for hepatitis C, might be able to prevent or treat COVID-19 outside of a clinical setting.

The São Paulo Patient is no longer HIV-free after more than 15 months off treatment, but was it a relapse or reinfection?

A next-generation implant maintained adequate drug levels for at least a year in an early study.

MK-8507, a long-acting NNRTI, will be tested in a weekly regimen with islatravir.

None of the four drugs tested in the WHO’s Solidarity trial reduced mortality or duration of hospitalization.

MK-8507, a long-acting NNRTI, will be tested in a weekly regimen with islatravir.

The study asks whether certain approved therapies or late-stage investigational drugs show promise against COVID-19.

An experimental approach to protect HIV-fighting T cells has been cleared for its first human trial.

New mRNA vaccine approach protects monkeys from HIV-like virus.

New mRNA vaccine approach protects monkeys from HIV-like virus.

An experimental approach to protect HIV-fighting T cells has been cleared for its first human trial.